New Independent Clinical Data Released on Corgenix Medical Corporation AspirinWorks(R) Test Kit

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced that publication of the latest clinical data for the AspirinWorks® Test, which measures aspirin effectiveness, was released this week at the XXIst Congress of the International Society on Thrombosis and Hemostasis (ISTH) meeting in Geneva, Switzerland. Investigators reported that AspirinWorks is an effective way to measure urinary 11-Dehydro Thromboxane B2, a metabolite of thromboxane production, the target of aspirin therapy.

MORE ON THIS TOPIC